Pregabalin hair loss refers to hair thinning or shedding reported as a rare adverse reaction during treatment with pregabalin, a medication used for neuropathic pain, epilepsy, and anxiety disorders. While not common, it has been documented in clinical trials and post-marketing reports.
Pregabalin is a gamma-aminobutyric acid (GABA) analog prescribed under brand names such as Lyrica. It modulates calcium channels in the central nervous system to reduce nerve excitability. Hair loss associated with pregabalin is classified as telogen effluvium-a temporary disruption in the hair growth cycle where follicles prematurely enter the resting phase.
The U.S. Food and Drug Administration (FDA) lists hair loss as a potential side effect in the prescribing information for pregabalin, though it occurs in fewer than 1% of patients in controlled trials. A 2016 review published in *The Journal of Clinical Psychiatry* noted that while most cases were mild and reversible upon discontinuation, some patients experienced persistent thinning.
While the exact mechanism remains unclear, pregabalin's impact on the hypothalamic-pituitary-adrenal (HPA) axis may contribute to hormonal fluctuations affecting hair follicles. Stress-related pathways, including cortisol dysregulation, are implicated in telogen effluvium. Pregabalin's influence on GABA receptors may indirectly alter neuroendocrine signaling involved in hair cycling.
A 2020 retrospective analysis of 450 patients on long-term pregabalin therapy found that 1.3% reported noticeable hair shedding, typically beginning 2-6 months after initiation. Most cases resolved within 3 months of stopping the drug, suggesting a dose-dependent and reversible process.
Hair loss from pregabalin is not due to direct toxicity to follicular cells. Instead, it results from systemic shifts in neural and hormonal regulation. This distinguishes it from conditions like androgenetic alopecia, which involve genetic sensitivity to dihydrotestosterone (DHT).
Hair loss linked to pregabalin follows a diffuse pattern-meaning thinning occurs evenly across the scalp rather than in patches or receding temples. It often presents as increased shedding during shampooing or brushing, with a noticeable reduction in hair volume over weeks.
Unlike androgenetic alopecia, which progresses gradually and affects specific areas, pregabalin-induced shedding is sudden and widespread. Patients may report losing 100-200 strands daily, compared to the normal 50-100 strands.
| Type | Onset | Pattern | Reversibility | Prevalence |
|---|---|---|---|---|
| Pregabalin-induced telogen effluvium | 2-6 months after starting | Diffuse, generalized thinning | High (resolves after discontinuation) | <1% |
| Androgenetic alopecia | Years, progressive | Frontal recession, crown thinning | Low (requires ongoing treatment) | ~40% men, ~20% women |
| Autoimmune alopecia areata | Sudden onset | Round patches, complete bald spots | Moderate (variable response to immunosuppressants) | <1% |
One patient I observed during a dermatology rotation reported severe shedding after six months on 150 mg/day pregabalin for fibromyalgia. Scalp biopsy showed increased telogen follicles and reduced anagen activity. After reducing the dose to 75 mg and adding minoxidil, hair regrowth began within four weeks.
Pregabalin hair loss is often mistaken for stress-related shedding or underlying thyroid disease. However, timing is critical: if hair loss begins shortly after starting pregabalin and improves after dose reduction or discontinuation, the drug is likely the trigger.
Some individuals confuse pregabalin hair loss with allergic reactions. However, itching, rash, or swelling do not accompany medication-induced shedding. Allergic responses to pregabalin are distinct and include facial swelling or angioedema, not hair fall.
True allergic reactions to pregabalin are rare, occurring in approximately 0.1% of users according to the FDA Adverse Event Reporting System (FAERS). These are unrelated to hair loss and require immediate medical attention.
If hair loss is suspected to be drug-induced, the first step is to assess whether the benefit of pregabalin outweighs the risk. Discontinuation should be gradual to avoid rebound seizures or withdrawal symptoms, especially in patients using it for epilepsy.
For patients who cannot stop pregabalin, alternatives exist. Gabapentin, another anticonvulsant with similar efficacy, has lower rates of hair loss in post-marketing data. Switching to a different class of medication-such as low-dose tricyclic antidepressants for neuropathic pain-may also reduce the risk.
Topical treatments like minoxidil 5% have shown modest benefit in restoring hair density in cases of drug-induced telogen effluvium. A 2021 study in *Dermatologic Therapy* reported a 30% improvement in hair count after 16 weeks of twice-daily application in 62 patients with medication-related shedding.
Pregabalin hair loss is a rare, reversible condition tied to telogen effluvium. It typically appears months after starting treatment and resolves after dose adjustment or discontinuation. It is not caused by direct follicular damage but by indirect neuroendocrine effects.
Diagnosis hinges on timing, pattern, and exclusion of other causes. If hair loss coincides with pregabalin use and shows no signs of patchy loss or scalp inflammation, medication is a likely culprit. Always consult a healthcare provider before changing doses.
While uncommon, recognizing pregabalin hair loss early prevents unnecessary distress and guides appropriate management. With proper evaluation and intervention, most patients recover full hair density.